So, in the opening remarks, you mentioned that FY '26 was a year of transition. So, I presume you're referring to the move from product focused to a therapy-focused approach.
And you also mentioned about the breakup of the segment revenue. I think you mentioned Infusion vertical has gone down to 52% and Renal has gone up to 11%. I could not capture the other percentages between Cardio and Onco.